flow trial glp 1 Ozempic® (semaglutide injection) GLP-1 medications are not just
Description
2021;16:e0247307
Expected 12-month results include 15 to 20% body weight loss (65 to 100+ pounds for a 400-pound person), 6 to 10 inch waist circumference reduction, transformative improvement in daily functional capacity, and resolution or significant improvement of multiple obesity-related conditions
Preclinical and clinical evidence suggests GLP-1 agonists may have mild mood-stabilizing properties, potentially complementing sertraline's anxiolytic effects
Abbott Laboratories (NYSE: ABT | ABT Price Prediction) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets
& Sokolowski, C
Notably, the glucoregulatory and anorectic activities of GIP and GLP-1 have supported development of incretin-based therapies for the treatment of type 2 diabetes and obesity
